Genome Profiling, Fox Chase Cancer Center to Collaborate on Immune System Blood Test to Predict Checkpoint Inhibitor Response in Non-Small Cell Lung Cancer
PHILADELPHIA (July 13, 2020) – Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody. These agents are a potentially valuable tool for lung cancer treatment, but it remains very difficult for doctors to predict which patients are most likely to benefit from them.